Division of Nutritional Sciences, Cornell University, Ithaca, NY, United States.
Front Endocrinol (Lausanne). 2022 May 26;13:889923. doi: 10.3389/fendo.2022.889923. eCollection 2022.
Obesity and its' associated metabolic diseases such as type 2 diabetes and cardiometabolic disorders are significant health problems confronting many countries. A major driver for developing obesity and metabolic dysfunction is the uncontrolled expansion of white adipose tissue (WAT). Specifically, the pathophysiological expansion of visceral WAT is often associated with metabolic dysfunction due to changes in adipokine secretion profiles, reduced vascularization, increased fibrosis, and enrichment of pro-inflammatory immune cells. A critical determinate of body fat distribution and WAT health is the sex steroid estrogen. The bioavailability of estrogen appears to favor metabolically healthy subcutaneous fat over visceral fat growth while protecting against changes in metabolic dysfunction. Our review will focus on the role of estrogen on body fat partitioning, WAT homeostasis, adipogenesis, adipocyte progenitor cell (APC) function, and thermogenesis to control WAT health and systemic metabolism.
肥胖及其相关代谢性疾病,如 2 型糖尿病和心脏代谢紊乱,是许多国家面临的重大健康问题。肥胖和代谢功能障碍的一个主要驱动因素是白色脂肪组织(WAT)的不受控制的扩张。具体而言,内脏 WAT 的病理生理扩张通常与由于脂联素分泌谱的变化、血管生成减少、纤维化增加和促炎免疫细胞富集而导致的代谢功能障碍相关。决定体脂分布和 WAT 健康的关键因素是性激素雌激素。雌激素的生物利用度似乎有利于代谢健康的皮下脂肪而不是内脏脂肪的生长,同时防止代谢功能障碍的变化。我们的综述将重点讨论雌激素对体脂分布、WAT 稳态、脂肪生成、脂肪细胞祖细胞(APC)功能和产热的作用,以控制 WAT 健康和全身代谢。